Fierce Biotech August 12, 2024
The initial stages of oncology R&D aren’t short of intriguing new modalities, and Halda Therapeutics is planning to join them by using $126 million in fresh funding to bring its RIPTAC program into the clinic.
RIPTAC—which stands for Regulated Induced Proximity Targeting Chimeras—is being billed by the biotech as a novel “hold and kill” mechanism. In practice, this means developing a heterobifunctional molecule that targets two proteins—a cancer-specific protein and a protein with an essential function—which can kill a cancer cell while sparing non-cancerous tissue that doesn’t express the cancer-specific protein.
This “oral, selective, and widely applicable cancer cell-killing mechanism … is designed to overcome drug resistance, which is a major shortcoming of many current standard of care cancer treatments,”...
Today's Sponsors
Today's Sponsor